The
FDA
approved
ropeginterferon
alfa-2b
(Besremi)
injection
to
treat
adults
with
essential
thrombocythemia,
the
first
new
therapy
for
the
chronic
blood
cancer
since
the
1997
approval
of
anagrelide.
A
national
survey
showed
that
almost
40%
of
men
55
or
older
had
never
had
a
prostate-specific
antigen
(PSA)
screening
test
for
prostate
cancer.
(MedStar
Health)
In
a
preliminary
study,
a
blood
test
for
early
detection
of
lung
cancer
achieved
94%
sensitivity
and
97%
negative
predictive
value.
(Clinical
Lab
Products)
Patients
receiving
cancer
treatment
at
Anne
Arundel
Medical
Center
in
Maryland
had
to
be
rescheduled
at
other
facilities
after
a
cyberattack
disrupted
computer
systems.
(WBAL-TV
11)
Drug
distributor
and
healthcare
supply
company
McKesson
acknowledged
that
unauthorized
individuals
stole
data
affecting
customers
in
its
oncology,
multispecialty,
and
medical-surgical
businesses.
Artificial
intelligence
can
pick
up
breast
cancers
missed
by
mammography,
but
does
it
really
make
a
difference?
(UCLA
Health)
Advances
in
risk
stratification,
new
bladder-preserving
treatment
options,
and
new
information
about
biomarkers
and
emerging
therapies
highlight
an
update
to
the
American
Urological
Association/Society
of
Urologic
Oncology
clinical
guideline
for
non-invasive
bladder
cancer.
A
urine
test
for
bladder
cancer
detected
more
than
90%
of
cancers
in
almost
1,000
patients
referred
for
evaluation.
(University
of
Birmingham)
Colon
cancer
in
people
50
or
younger
has
a
different
biology
and
survival
compared
with
disease
in
older
patients.
(Medical
Journal
of
Australia)
Patients
with
resectable
non-small
cell
lung
cancer
(NSCLC)
and
a
pathologic
complete
response
after
neoadjuvant
therapy
did
not
benefit
from
adjuvant
immunotherapy.
(Chinese
Medical
Journal)
The
bispecific
antibody
ivonescimab
led
to
better
overall
survival
versus
pembrolizumab
(Keytruda)
in
a
phase
III
study
of
patients
with
PD-L1-positive
locally
advanced/metastatic
NSCLC,
Summit
Therapeutics
announced.
AbbVie
announced
that
the
bispecific
T-cell
engager
etentamig
significantly
improved
response
rate
and
progression-free
survival
versus
standard
therapy
in
a
phase
III
trial
of
relapsed/refractory
multiple
myeloma.
Please
enable
JavaScript
to
view
the